Skip to main content

Table 3 Univariate analysis of potential prognostic factors associated with hepatitis in HBsAg-negative DLBCL patients

From: Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival

Factor

Without hepatitis [cases (%)]

With hepatitis [cases (%)]

P value

Total

144

21

 

HBcAb

  

0.013

 –

101 (70.1)

9 (42.9)

 

 +

43 (29.9)

12 (57.1)

 

HBeAb

  

1.000

 –

131 (91.0)

19 (90.5)

 

 +

13 (9.0)

2 (9.5)

 

Age (years)

  

0.399

 ≤60

62 (43.1)

7 (33.3)

 

 >60

82 (56.9)

14 (66.7)

 

Sex

  

0.756

 Female

60 (41.7)

8 (38.1)

 

 Male

84 (58.3)

13 (61.9)

 

ECOG PS

  

0.500

 0–1

125 (86.8)

17 (81.0)

 

 ≥2

19 (13.2)

4 (19.0)

 

B symptoms

  

0.726

 −

108 (75.0)

15 (71.4)

 

 +

36 (25.0)

6 (28.6)

 

Ann Arbor stage

  

0.129

 I–II

73 (50.7)

7 (33.3)

 

 III-IV

70 (48.6)

14 (66.7)

 

Liver involvement

  

0.598

 −

136 (94.4)

21 (100)

 

 +

8 (5.6)

0 (0)

 

Spleen involvement

  

1.000

 −

131 (91.0)

19 (90.5)

 

 +

13 (9.0)

2 (9.5)

 

Involved extranodal sites

  

0.586

 <2

111 (77.1)

15 (71.4)

 

 ≥2

33 (22.9)

6 (28.6)

 

Bone marrow involvement

  

1.000

 −

134 (93.1)

20 (95.2)

 

 +

10 (6.9)

1 (4.8)

 

IPI score

  

0.180

 0–1

63 (43.8)

6 (28.6)

 

 2–5

80 (55.8)

15 (71.4)

 

ALT

  

0.013

 ≤40 U/L

128 (88.9)

14 (66.7)

 

 >40 U/L

16 (11.1)

7 (33.3)

 

AST

  

0.019

 ≤45 U/L

131 (91.0)

15 (71.4)

 

 >45 U/L

13 (9.0)

6 (28.6)

 

TB

  

0.696

 ≤20.5 μmol/L

129 (89.6)

20 (95.2)

 

 >20.5 μmol/L

15 (10.4)

1 (4.8)

 

LDH

  

0.728

 ≤245 U/mL

88 (61.1)

12 (57.1)

 

 >245 U/mL

56 (38.9)

9 (42.9)

 
  1. Footnotes as in Table 1.